Sanofi Commences Tender Offer for Acquisition of Bioverativ

Sanofi (NASDAQ:SNY) announced that on February 7, 2018 it commenced a tender offer to acquire all of the outstanding shares of common stock of Bioverativ (NASDAQ:BIVV), for $105 per share in cash without interest thereon and net of any required tax withholding. The Offer is being made pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 by and among Bioverativ, Sanofi and Blink Acquisition Corp., a Delaware corporation and an indirect, wholly-owned subsidiary of Sanofi.

As quoted in the press release:

The consummation of the Offer is subject to various conditions, including the tender of at least a majority of the shares of common stock of Bioverativ outstanding immediately prior to the expiration of the Offer, redelivery of a tax opinion delivered at signing, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and receipt of certain other regulatory approvals.

Click here to read the full press release.